• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly & Co.

Glooko adds former Eli Lilly exec to its board of directors

April 27, 2022 By Sean Whooley

Glooko Logo

Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors. Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units. According to a news release, […]

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology Tagged With: Eli Lilly, Eli Lilly & Co., glooko, Personnel, Personnel Moves

Eli Lilly to build $1B manufacturing facility for injectable products, devices in North Carolina

January 28, 2022 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1 billion to create a new manufacturing site in North Carolina. Indianapolis-based Eli Lilly’s new facility, which it expects will create nearly 600 jobs in Concord, North Carolina, will manufacture parenteral (injectable) products and devices while increasing the company’s manufacturing capacity. The company […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Personnel, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Your favorite articles from Drug Delivery Business News in 2021

December 29, 2021 By Sean Whooley

Drug Delivery Business News

From continuous glucose monitors to insulin pens, plus needle-free injection devices and inhalers — here are the most popular articles on Drug Delivery Business News from 2021:   Links to your favorite articles: Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Eli Lilly partners with four companies on insulin pen tech Scancell picks PharmaJet’s needle-free […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Respiratory Tagged With: Dexcom, Eli Lilly, Eli Lilly & Co., Garmin, Pear Therapeutics, PharmaJet, Scancell, Teva Pharmaceuticals

How some diabetes tech companies are honoring National Diabetes Month

November 17, 2021 By Sean Whooley

World Diabetes day

World Diabetes Day (Nov. 14) may have passed, but it remains National Diabetes Month through the end of November. A number of companies developing some of the most intriguing innovations in diabetes care have also stepped forward this month to organize awareness-raising efforts for the metabolic disease. Here are some steps a handful of diabetes […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, Dexcom, Eli Lilly & Co., Insulet, Medtronic

7 diabetes treatment innovations to look out for on World Diabetes Day

November 15, 2021 By Sean Whooley

World Diabetes day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pharmaceuticals Tagged With: Dexcom, Diabeloop, Eli Lilly, Eli Lilly & Co., Fractyl Health, Insulet, Medtronic, Senseonics, Twin Health

Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes

October 21, 2021 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes. Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Eli Lilly to donate nearly $1M to Type 1 diabetes initiative

September 7, 2021 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it will commit nearly $1 million over the next three years toward helping children with Type 1 diabetes. Indianapolis-based Eli Lilly, in a joint effort with the Leona M. and Harry B. Helmsley Charitable Trust, seeks to promote greater access to care and resources while inspiring confidence for children […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Eli Lilly, Eli Lilly & Co.

Eli Lilly forms neuroscience and immunology units amid leadership changes

August 17, 2021 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced executive leadership changes as it creates neuroscience and immunology business units. Indianapolis-based Eli Lilly split its bio-medicines segment into Lilly Neuroscience and Lilly Immunology in the organizational shift, to be made effective Sept. 5, with Anne White set to lead the neuroscience unit and Patrik Jonsson set to head up […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co., Lilly Immunology, Lilly Neuroscience, Personnel, Personnel Moves

FDA approves, expands label for Eli Lilly’s rapid-acting insulin for infusion

August 16, 2021 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it received FDA approval and expanded labeling for its Lyumjev rapid-acting insulin. Indianapolis-based Eli Lilly’s Lyumjev (insulin lispro-aabc injection) 100 units/mL holds indication to improve glycemic control in adults with type 1 and type 2 diabetes, including administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump. The […]

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Eli Lilly, Eli Lilly & Co., FDA, Lyumjev, rapid-acting insulin

Eli Lilly acquires glucose-sensing insulin developer Protomer Technologies

July 14, 2021 By Sean Whooley

Eli Lilly Protomer

Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies. Pasadena, Calif.-based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Indianapolis-based Eli Lilly said in a news release that the potential value of the transaction […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Eli Lilly, Eli Lilly & Co., Protomer Technologies

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS